- Home
- BEAG vs ESPR Comparison
BEAG vs ESPR Comparison
Compare BEAG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAG
- ESPR
- Stock Information
- Founded
- BEAG 2021
- ESPR 2008
- Country
- BEAG United States
- ESPR United States
- Employees
- BEAG N/A
- ESPR N/A
- Industry
- BEAG
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- BEAG
- ESPR Health Care
- Exchange
- BEAG NYSE
- ESPR Nasdaq
- Market Cap
- BEAG 314.4M
- ESPR 305.0M
- IPO Year
- BEAG 2024
- ESPR 2013
- Fundamental
- Price
- BEAG $10.13
- ESPR $1.63
- Analyst Decision
- BEAG
- ESPR Buy
- Analyst Count
- BEAG 0
- ESPR 7
- Target Price
- BEAG N/A
- ESPR $6.36
- AVG Volume (30 Days)
- BEAG 156.3K
- ESPR 4.5M
- Earning Date
- BEAG 01-01-0001
- ESPR 03-04-2025
- Dividend Yield
- BEAG N/A
- ESPR N/A
- EPS Growth
- BEAG N/A
- ESPR N/A
- EPS
- BEAG 0.08
- ESPR N/A
- Revenue
- BEAG N/A
- ESPR $332,314,000.00
- Revenue This Year
- BEAG N/A
- ESPR $5.51
- Revenue Next Year
- BEAG N/A
- ESPR $1.42
- P/E Ratio
- BEAG $133.19
- ESPR N/A
- Revenue Growth
- BEAG N/A
- ESPR 185.66
- 52 Week Low
- BEAG $10.00
- ESPR $1.47
- 52 Week High
- BEAG $10.57
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- BEAG N/A
- ESPR 45.89
- Support Level
- BEAG N/A
- ESPR $1.47
- Resistance Level
- BEAG N/A
- ESPR $1.75
- Average True Range (ATR)
- BEAG 0.00
- ESPR 0.11
- MACD
- BEAG 0.00
- ESPR 0.03
- Stochastic Oscillator
- BEAG 0.00
- ESPR 57.14
About BEAG BOLD EAGLE ACQUISITION CORP
Bold Eagle Acquisition Corp is a blank check company.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.